TGTX Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of 4.63% compared to TG Therapeutics's net margin of -2357.27%. TG Therapeutics's return on equity of -8.4% beat Palatin Technologies's return on equity of --.

TG Therapeutics has a consensus price target of --, signalling upside risk potential of 26.71%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than TG Therapeutics, analysts believe Palatin Technologies is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.248, which suggesting that the stock is 124.789% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $83.9M, which are larger than Palatin Technologies quarterly revenues of $350K. TG Therapeutics's net income of $3.9M is higher than Palatin Technologies's net income of -$7.8M. Notably, TG Therapeutics's price-to-earnings ratio is 41.18x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.90x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of 4.63% compared to TG Therapeutics's net margin of -131.25%. TG Therapeutics's return on equity of -8.4% beat Rhythm Pharmaceuticals's return on equity of -208.96%.

TG Therapeutics has a consensus price target of --, signalling upside risk potential of 26.71%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $72.82 which suggests that it could grow by 30.38%. Given that Rhythm Pharmaceuticals has higher upside potential than TG Therapeutics, analysts believe Rhythm Pharmaceuticals is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.248, which suggesting that the stock is 124.789% more volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.141, suggesting its more volatile than the S&P 500 by 114.099%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $83.9M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $33.3M. TG Therapeutics's net income of $3.9M is higher than Rhythm Pharmaceuticals's net income of -$43.6M. Notably, TG Therapeutics's price-to-earnings ratio is 41.18x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.90x versus 29.98x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker has a net margin of 4.63% compared to TG Therapeutics's net margin of -2.12%. TG Therapeutics's return on equity of -8.4% beat Warby Parker's return on equity of -10.25%.

TG Therapeutics has a consensus price target of --, signalling upside risk potential of 26.71%. On the other hand Warby Parker has an analysts' consensus of $22.23 which suggests that it could fall by -13.57%. Given that TG Therapeutics has higher upside potential than Warby Parker, analysts believe TG Therapeutics is more attractive than Warby Parker.

TG Therapeutics has a beta of 2.248, which suggesting that the stock is 124.789% more volatile than S&P 500. In comparison Warby Parker has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Warby Parker pays out -- of its earnings as a dividend.

TG Therapeutics quarterly revenues are $83.9M, which are smaller than Warby Parker quarterly revenues of $192.4M. TG Therapeutics's net income of $3.9M is higher than Warby Parker's net income of -$4.1M. Notably, TG Therapeutics's price-to-earnings ratio is 41.18x while Warby Parker's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.90x versus 4.15x for Warby Parker. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 4.63% compared to TG Therapeutics's net margin of 28.56%. TG Therapeutics's return on equity of -8.4% beat Zoetis's return on equity of 48%.

TG Therapeutics has a consensus price target of --, signalling upside risk potential of 26.71%. On the other hand Zoetis has an analysts' consensus of $214.22 which suggests that it could grow by 30.07%. Given that Zoetis has higher upside potential than TG Therapeutics, analysts believe Zoetis is more attractive than TG Therapeutics.

TG Therapeutics has a beta of 2.248, which suggesting that the stock is 124.789% more volatile than S&P 500. In comparison Zoetis has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.103%.

TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.05% to investors and pays a quarterly dividend of $0.43 per share. TG Therapeutics pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

TG Therapeutics quarterly revenues are $83.9M, which are smaller than Zoetis quarterly revenues of $2.4B. TG Therapeutics's net income of $3.9M is lower than Zoetis's net income of $682M. Notably, TG Therapeutics's price-to-earnings ratio is 41.18x while Zoetis's PE ratio is 30.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 18.90x versus 8.23x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.